Intuniv vs. Adderall XR

See how Intuniv and Adderall XR compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Intuniv is a non-stimulant approved for ADHD in children and teens, while Adderall XR is a stimulant approved for both children and adults.

  • Intuniv can be added to a stimulant for extra symptom control, while Adderall XR carries a boxed warning for abuse, misuse, and addiction risk.

  • Both are taken once daily, but Intuniv needs a multi-week titration schedule while Adderall XR reaches an effective dose more quickly.

Intuniv vs. Adderall XR Drug Summary

Intuniv

Intuniv is a non-stimulant medication that activates alpha2A receptors in the brain to improve attention and impulse control. It is FDA-approved for ADHD in children and adolescents ages 6 to 17, used alone or added to a stimulant. It comes as an extended-release tablet taken once daily, morning or evening.

Adderall XR

Adderall XR is an extended-release stimulant containing a mix of amphetamine salts that raise dopamine and norepinephrine activity in the brain. It is FDA-approved for ADHD in children age 6 and older, adolescents, and adults, unlike Intuniv, which is not approved for adults. It is taken once daily as an extended-release capsule and is a Schedule II controlled substance.

Intuniv vs. Adderall XR Side Effects

Intuniv

Most common
somnolence (up to 38%)
headache (up to 24%)
fatigue (up to 14%)
abdominal pain (up to 11%)

Adderall XR

Most common
insomnia (up to 17%)
abdominal pain (up to 11%)
emotional lability (up to 7%)
vomiting (up to 7%)

Intuniv vs. Adderall XR Dosage

Intuniv

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 1 mg once daily Week 1
Maximum dose 4 mg once daily Week 4 onward
Dose changes 3 increases Every week

Adderall XR

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg once daily At the start
Maximum dose 10 mg once daily Same as starting
Dose changes None Fixed dose

Intuniv vs. Adderall XR Indications

Intuniv

Intuniv is FDA-approved for ADHD in children and adolescents ages 6 to 17, either as a standalone treatment or added to a stimulant regimen. It is not approved for adults, though doctors sometimes prescribe it off-label for adult ADHD.

  • Monotherapy for ADHD in ages 6-17

  • Adjunctive therapy with stimulants, ages 6-17

  • Off-label use in adults (not FDA-approved)

Adderall XR

Adderall XR is FDA-approved for ADHD in children ages 6 and older, adolescents, and adults, covering the full age range. It is not approved for children under 6 or for patients with end-stage renal disease.

  • ADHD treatment in children age 6 and older

  • ADHD treatment in adolescents

  • ADHD treatment in adults

Intuniv vs. Adderall XR Pros and Cons

Intuniv

Intuniv works gradually through a non-stimulant mechanism, making it an option for families who want to avoid stimulant side effects or add it to an existing stimulant regimen. It requires a step-up dosing schedule and a taper when stopping, and it is only approved for children and teens.

Pros

  • Non-stimulant option with no abuse potential or controlled-substance status

  • Can be combined with a stimulant for added symptom control

  • No boxed warning for abuse, misuse, or addiction

Cons

  • Requires several weeks of titration before reaching a maintenance dose

  • Not approved for adults, limiting use once a patient ages out of adolescence

  • Common side effects include sedation, low blood pressure, and slowed heart rate

  • Abrupt stopping can cause rebound high blood pressure, requiring a taper

Adderall XR

Adderall XR acts quickly as a stimulant and is approved across the full age range from childhood through adulthood, but it carries a boxed warning for abuse potential and added cardiovascular precautions. Its once-daily dosing is straightforward, without the multi-week titration Intuniv requires.

Pros

  • Approved for the full ADHD age range, including adults

  • Reaches an effective dose faster, with fewer dose-adjustment steps

  • Long track record since 2001 across children, teens, and adults

Cons

  • Schedule II controlled substance with a boxed warning for abuse, misuse, and addiction

  • Carries cardiovascular warnings, including sudden death in structural heart defects

  • Can cause appetite suppression and growth suppression with long-term pediatric use

  • Not recommended with amphetamine hypersensitivity or recent MAOI use

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.